Video

Giora Sharf Discusses Intentional, Unintentional Nonadherence in CML Patients

Although there is a clear link between nonadherence and outcomes of a patient with chronic myelogenous leukemia (CML), some patient intentionally stop taking their medication, said Giora Sharf, co-founder of the CML Advocates Network.

Although there is a clear link between nonadherence and outcomes of a patient with chronic myelogenous leukemia (CML), some patient intentionally stop taking their medication, said Giora Sharf, co-founder of the CML Advocates Network.

Some patients are unintentionally not adhering to their medication, sometimes because they simply forget, which the CML Advocates Network hopes combat through its new app.

However, there are times patients choose intentional nonadherence, often because the patient does not want to suffer from the side effects of the medication. Another dangerous barrier is when a patient feels fine, and stops treatment because he or she doesn’t see the point in taking it, Mr Sharf explained.

Related Videos
Toby Maher, MD, PhD, professor of clinical medicine, Keck School of Medicine at USC
Nini Wu, MD, Navista
Fred Locke, MD, Moffitt Cancer Center and Research Institute
Dr Emma Achola-Kothari
Matthew Viggiano, MD, internal medicine resident, Temple University Hospital
Krunal Patel, MD, pulmonary and critical care fellow, Temple University Hospital
M. Bradley Drummond, MD, MHS, professor of medicine, University of North Carolina at Chapel Hill
Dr Margrit Wiesendanger
Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia
Michael Goulet, DO, pulmonary and critical care fellow, Temple University Hospital
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo